MX343391B - Proceso para la preparación de 5h-pirimido[5,4-d]benzazepina. - Google Patents

Proceso para la preparación de 5h-pirimido[5,4-d]benzazepina.

Info

Publication number
MX343391B
MX343391B MX2012011398A MX2012011398A MX343391B MX 343391 B MX343391 B MX 343391B MX 2012011398 A MX2012011398 A MX 2012011398A MX 2012011398 A MX2012011398 A MX 2012011398A MX 343391 B MX343391 B MX 343391B
Authority
MX
Mexico
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
inhibiting
cancer
Prior art date
Application number
MX2012011398A
Other languages
English (en)
Spanish (es)
Inventor
F Claiborne Christopher
G Stroud Stephen
B Sells Todd
Original Assignee
Millenium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343391(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millenium Pharmaceuticals Inc filed Critical Millenium Pharmaceuticals Inc
Publication of MX343391B publication Critical patent/MX343391B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2012011398A 2006-11-16 2007-11-14 Proceso para la preparación de 5h-pirimido[5,4-d]benzazepina. MX343391B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
MX343391B true MX343391B (es) 2016-11-04

Family

ID=39315133

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2009004670A MX2009004670A (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresion mitotica.
MX2012011396A MX348568B (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresión mitótica.
MX2012011398A MX343391B (es) 2006-11-16 2007-11-14 Proceso para la preparación de 5h-pirimido[5,4-d]benzazepina.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2009004670A MX2009004670A (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresion mitotica.
MX2012011396A MX348568B (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresión mitótica.

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2497773B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101342014B1 (enExample)
CN (2) CN101547924B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2497772T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2537451T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX2009004670A (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ611898A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2497772T3 (enExample)
PT (2) PT2086981E (enExample)
RS (2) RS53788B1 (enExample)
SG (2) SG176443A1 (enExample)
SI (2) SI2497772T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261226B1 (en) 2004-05-14 2015-04-01 Millennium Pharmaceuticals, Inc. Methods for preparing aurora kinase inhibitors
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JP5684719B2 (ja) * 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
JP5738196B2 (ja) * 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2012140021A (ru) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
ES2526671T3 (es) * 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
JP6360881B2 (ja) * 2013-03-22 2018-07-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 触媒的ｍｔｏｒｃ１／２阻害薬及びオーロラａキナーゼの選択的阻害薬の組合せ
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗がん剤としての複素環式の限定された三環系スルホンアミド
JP6966425B2 (ja) 2015-09-09 2021-11-17 アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai 抗がん剤としての複素環式の限定された三環系スルホンアミド
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
MA71325A (fr) 2022-06-30 2025-04-30 Eli Lilly And Company Inhibiteur de kras g12c pour le traitement du cancer
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) * 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
IL135303A0 (en) * 1997-09-29 2001-05-20 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
WO2001042199A1 (en) 1999-12-06 2001-06-14 Ajinomoto Co.,Inc. Amidinophenylpyruvic acid derivative
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
CN100418955C (zh) 2001-08-09 2008-09-17 埃科特莱茵药品有限公司 新型苯并稠杂环
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP2261226B1 (en) 2004-05-14 2015-04-01 Millennium Pharmaceuticals, Inc. Methods for preparing aurora kinase inhibitors
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
DK2086981T3 (da) 2012-08-06
US20210214361A1 (en) 2021-07-15
CN103483343B (zh) 2016-06-01
BRPI0718803B8 (pt) 2021-05-25
US20240400567A1 (en) 2024-12-05
NZ611898A (en) 2015-01-30
JP5102839B2 (ja) 2012-12-19
HK1217699A1 (en) 2017-01-20
EP2497773B1 (en) 2015-02-25
CN101547924B (zh) 2013-09-25
JP2014055166A (ja) 2014-03-27
CL2007003244A1 (es) 2008-04-04
UA94129C2 (ru) 2011-04-11
PH12012502057B1 (en) 2018-10-24
KR101342014B1 (ko) 2013-12-19
CR20140154A (es) 2014-07-23
HRP20150047T1 (en) 2015-03-13
MX348568B (es) 2017-06-20
SI2086981T1 (sl) 2012-12-31
NO20091864L (no) 2009-06-15
EP2497772B1 (en) 2014-10-29
CN103483343A (zh) 2014-01-01
US10836766B2 (en) 2020-11-17
RS52313B (sr) 2012-12-31
ES2384123T3 (es) 2012-06-29
US20080167292A1 (en) 2008-07-10
ES2537451T3 (es) 2015-06-08
MA30988B1 (fr) 2009-12-01
RS53788B1 (sr) 2015-06-30
ZA200903279B (en) 2010-07-28
AU2007322046A1 (en) 2008-05-29
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
EP2497772A1 (en) 2012-09-12
JP2010510215A (ja) 2010-04-02
MY153243A (en) 2015-01-29
CA2669680A1 (en) 2008-05-29
EP2944639B1 (en) 2017-01-04
AR064246A1 (es) 2009-03-25
US9765076B2 (en) 2017-09-19
SG176443A1 (en) 2011-12-29
NZ577042A (en) 2012-03-30
HK1134672A1 (en) 2010-05-07
NO343338B1 (no) 2019-02-04
EP2086981B1 (en) 2012-05-02
KR20090091173A (ko) 2009-08-26
CA2669680C (en) 2012-04-10
SG10201503350TA (en) 2015-06-29
US8026246B2 (en) 2011-09-27
US20110312942A1 (en) 2011-12-22
DK2497772T3 (en) 2015-01-19
SI2497772T1 (sl) 2015-03-31
US20150166545A1 (en) 2015-06-18
US11958855B2 (en) 2024-04-16
EA015779B1 (ru) 2011-12-30
ES2528793T3 (es) 2015-02-12
HK1175778A1 (en) 2013-07-12
PL2086981T3 (pl) 2012-09-28
BRPI0718803B1 (pt) 2020-11-17
JP5452811B2 (ja) 2014-03-26
EP2497773A1 (en) 2012-09-12
JP2012006965A (ja) 2012-01-12
US20110312943A1 (en) 2011-12-22
NZ597252A (en) 2013-06-28
CR10782A (es) 2009-06-24
EA200970486A1 (ru) 2009-10-30
HK1175777A1 (en) 2013-07-12
PH12012502057A1 (en) 2015-09-14
BRPI0718803A2 (pt) 2013-12-03
CN101547924A (zh) 2009-09-30
EP2944639A1 (en) 2015-11-18
WO2008063525A1 (en) 2008-05-29
US9988384B2 (en) 2018-06-05
ATE556076T1 (de) 2012-05-15
CY1112828T1 (el) 2016-02-10
US20190031662A1 (en) 2019-01-31
KR20110113210A (ko) 2011-10-14
GEP20125459B (en) 2012-03-26
IL198690A0 (en) 2010-02-17
PT2497772E (pt) 2015-02-05
PL2497772T3 (pl) 2015-05-29
HRP20120490T1 (hr) 2012-07-31
EP2086981A1 (en) 2009-08-12
CR20140544A (es) 2015-01-12
TWI401255B (zh) 2013-07-11
TW200829589A (en) 2008-07-16
AU2007322046B2 (en) 2012-04-05
KR101110458B1 (ko) 2012-03-13

Similar Documents

Publication Publication Date Title
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
MY148634A (en) Pyridazinone derivatives
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
WO2009155121A3 (en) Inhibitors of pi3 kinase
SG179418A1 (en) Inhibitors of the hedgehog pathway
TW200800963A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
PL1853588T3 (pl) Związki chemiczne
NZ577916A (en) Cyclopamine analogs
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2010039668A3 (en) Inhibitors of cyclin kinase inhibitor p21
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.
IL191670A0 (en) Compounds for the inhibition of apoptosis
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
MY159181A (en) Use of an anti-cancer compound
EP1905773A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase